Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma

Table 2 The LEP (-2548) G/A and LEPR Q223R Genotype distributions in Control Subjects and in Patients with Breast Carcinoma.

Genotypes	Patients (n = 308)		Controls (n = 222)		OR	Confidence interval	P-value
	n	f	n	f
*LEP (* -2548) *G/A*
GG	119	(0.386)	112	(0.504)	1
GA	152	(0.494)	99	(0.446)	1.45	[0.99–2.11]	0.04
AA	37	(0.120)	11	(0.050)	3.17	[1.47–6.96]	0.001
Alleles
G-allele	390	(0.633)	323	(0.727)
A-allele	226	(0.367)	121	(0.273)	1.55	[1.18–2.04]	0.001
*LEPR Q223R*
QQ	98	(0.318)	102	(0.460)	1
QR	145	(0.471)	90	(0.405)	1.68	[1.12–2.50]	0.007
RR	65	(0.211)	30	(0.135)	2.26	[1.31–3.90]	0.001
Alleles
Q-allele	341	(0.554)	294	(0.662)
R-allele	275	(0.446)	150	(0.338)	158	[1.22–2.05]	0.0003

OR, odds ratio; CI, confidence interval. The χ² test was used to determine whether significant differences (P-value) were observed when the patient group was compared with the control group. f, frequencies.

ISSN: 1471-2407